Mission Bio’s Tapestri Platform Can Now Identify Both Mutations and Copy Number Variants from the Same Cells

 

New product capabilities position the Tapestri Platform as the only solution to perform comprehensive single-cell DNA analysis

 

SAN FRANCISCO, Calif. (August 22, 2019) Mission Bio, Inc., the pioneer in targeted single-cell DNA analysis and precision genomics, today announced the launch of Copy Number Analysis, extending Copy Number Variation (CNV) capabilities to its Tapestri Platform with no changes to the current workflow. With this latest capability, Mission Bio’s Tapestri® Platform now stands as the first and only commercial platform for single-cell DNA analysis, with comprehensive insight into mutations and CNVs from the same cell on a single platform, expanding the company’s leadership in single-cell DNA analysis for oncology.

CNVs, where portions of the chromosome are amplified or deleted, are the cause of many genetic disorders and are present in nearly all types of cancers. When determining the clonal heterogeneity across a cancer sample, it’s important to comprehensively measure both DNA mutations and copy number alterations in every cell because disease progression and therapy response are based on differences in genetic alterations across cells. This includes both single nucleotide variations (SNVs), which are prognostic and provide insight into the disease development and progression, and CNVs, which tend to predict the severity of the disease.

“Access to both SNVs and CNVs at the single-cell level, from the same cell, gives us higher resolution to explore tumor evolution and disease progression,” said Samra Turajlic, M.D., of Francis Crick Institute. “We look forward to analyzing these novel data types to help us better resolve the genetic and cellular heterogeneity in cancer.”

Mission Bio’s high-throughput single-cell DNA analysis on the Tapestri Platform yields unprecedented insight into the diversity of genomic changes found in individual cancer cells. Moreover, for the first time, CNVs and SNVs can be measured from the same single cell across thousands of cells. With the Tapestri Platform, researchers and clinicians can now leverage a single platform to measure nearly every type of DNA change in every diseased cell. This results in significant cost savings and improved workflow, all while enabling even deeper insight into patterns of tumor evolution, therapy response, and resistance.

“The ability to pair mutations and gene-level to chromosome-level copy number from the same cell has never before been available for single-cell DNA analysis, let alone on a single platform,” said Nigel Beard, SVP of Research and Development (R&D) at Mission Bio. “With the launch of Copy Number Analysis on the Tapestri Platform, we’re enabling the full picture of any variation at the DNA level, giving unprecedented insights that will accelerate cancer research and enable precision medicine.”

Mission Bio has demonstrated the Tapestri Platform’s ability to track and monitor cancer evolution with single-cell precision with numerous peer-reviewed studies, including the most recent in Cancer Discovery, which examined the Tapestri Platform’s use in Acute Myeloid Leukemia (AML) research.

To learn more about Mission Bio and how it’s moving precision medicine forward, visit cnmissionbio.wpengine.com.

 

About Mission Bio
Mission Bio delivers targeted solutions for high impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and software, which plug seamlessly into existing NGS workflows. LabCorp’s Covance Drug Development business will be the first global contract research organization to offer services on the Mission Bio Tapestri Platform, supporting biopharmaceutical customers in their need for faster, more precise clinical trials.

The company’s Tapestri Platform was also honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

 

Media Contact:
Kathryn Ryan
VSC for Mission Bio
missionbio@vscconsulting.com
(631) 255-5281